Early Life
Herriot Tabuteau was born in Haiti and immigrated to the United States at age nine, settling in New York City. He attended Xavier High School, and later pursued a degree in molecular biology and biochemistry at Wesleyan University, graduating in 1989. He then went on to Yale School of Medicine, earning his M.D. in 1994.
Rise to Success
Initially planning a career in neurosurgery, Tabuteau transitioned to finance, working in healthcare investment banking at Goldman Sachs and later at Healthco/S.A.C. Capital, a healthcare-focused hedge fund. In 2012, he founded Axsome Therapeutics. The company, named after parts of a nerve cell (axon and soma), focuses on developing treatments for brain disorders. Axsome went public in 2015. Under Tabuteau’s leadership, Axsome has brought several innovative drugs to market, including Auvelity for major depressive disorder, which received FDA approval in 2022, and Symbravo for migraines.
Key Business Strategies
Tabuteau's approach to drug development differed from the industry norm. Instead of relying on a single drug, he built a portfolio to reduce risk. He also kept costs low by running in-house clinical trials, offering a more cost-effective approach. His expertise in finance also played a key role in the company’s success, including the acquisition of Sunosi for excessive daytime sleepiness, which was later sold for a profit.
Philanthropy
Information regarding Herriot Tabuteau's specific philanthropic initiatives is limited in the search results. However, his work at Axsome Therapeutics, focused on treating brain disorders, indicates a commitment to improving patient outcomes, which can be seen as a form of philanthropy.
